Prediction: The Future of Next Generation Sequencing in 2021

According to a recent report from Marketsand Markets, the global next-generation sequencing (NGS) market is expected to witness the rapid growth of its product technology between 2016 and 2021, and the market is expected to reach US$10.37 billion by 2021. NGS product technology advancement, application increase, entry of new market players, increased collaboration among manufacturers, growing cancer and rare diseases, and prenatal and neonatal diseases all contribute to the expansion of the NGS market.

The global NGS market is roughly subdivided into products, services, technologies, applications, and end users. The products and services of the NGS market are divided into predictive products and services, NGS platforms, consumables, sequencing services, and data analysis/bioinformatics.

The technical divisions of the global NGS market include: pyrophosphate sequencing (SBP), sequencing by synthesis (SBS), single molecule real-time sequencing (SMRT), sequencing by sequencing (SBL) and ion semiconductor sequencing. In 2016, synthetic sequencing (SBS) is expected to occupy the largest share of the global NGS market.

Divided by application, the global NGS market includes: diagnosis, drug development, biomarker research, personalized medicine, agriculture and animal research, and others (marine, forensic, and biofuel research). In 2016, diagnostic applications are expected to account for the largest share of the global NGS market.

The end users of the global NGS market include: research centers and academic/government agencies, hospitals and clinics, pharmaceutical and biotechnology companies, and others. In 2016, research centers and academic/government agencies are expected to account for the largest share of the NGS market.

The global NGS market report covers four major regions in North America, Europe, Asia Pacific and the rest of the world. In 2016, North America is expected to maintain its position as the largest share of the global NGS market, and between 2016 and 2021, the Asia Pacific region may be the fastest growing market. The improvement of the medical infrastructure in the Asia-Pacific region and its good government initiatives are expected to drive the NGS market in the region.

Major companies in the global NGS market include: Illumina (USA), Thermo Fisher (USA), Pacific Biosciences of California (USA), Roche (Switzerland), QIAGEN NV (Germany), BGI (China), Macrogen, (Korea), Eurofins (Luxembourg), Oxford Nanopore (UK) and others.